Tailored treatment for acute breathing problems
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests whether using a blood test to measure inflammation (IL-6) can help doctors decide if you should get either dexamethasone or tocilizumab for COVID-19 or other acute breathing problems. The goal is to find the best treatment faster and reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a new breathing problem (like cough, shortness of breath, or needing oxygen) that started within the last 2 weeks.
- You must be in the hospital and need ongoing care.
- You cannot be pregnant or breastfeeding.
- You cannot already be on powerful immune-suppressing medicines (like systemic steroids, monoclonal antibodies, or certain chemotherapy drugs).
- Your blood counts and liver/kidney function must be within safe limits as checked by your doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether dexamethasone (a steroid medicine) improves outcomes in adults who have sudden, severe breathing failure caused by an infection while they are on a breathing machine. It may help reduce inflammation in the lungs during critical illness.
This trial tests a new cell therapy using Treg cells from thymic tissue to calm an overactive immune response in severe COVID-19 and ARDS. It aims to improve breathing and reduce inflammation.
This trial tests if the drug tocilizumab can help treat acute chest syndrome, a serious lung complication of sickle cell disease. It is for people with sickle cell disease who are hospitalized and need oxygen or breathing support. The study compares tocilizumab to a placebo to see if it speeds up recovery.
This study tests whether a corticosteroid (a type of anti-inflammatory medicine) can help people with severe breathing problems or serious infections who have a specific 'hyperinflammatory' pattern. If you are in the ICU on a ventilator, this trial may be an option for you.
This Phase 3 study tests tozorakimab to see if it helps people hospitalized with a viral lung infection that is causing low oxygen levels. You might qualify if you still need supplemental oxygen when the study starts.
This trial studies tocilizumab (a medicine that calms inflammation) to treat acute chest syndrome in people with sickle cell disease. It may help improve symptoms and recovery by targeting key immune signals involved in this complication.
Hear when a new Acute Hypoxemic Respiratory Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.